chufangao/CTO huggingface dataset:
Clinical trial NCT04731740: Pembrolizumab and Lenvatinib/Chemotherapy for Poorly Differentiated/Anaplastic Thyroid Cancer
Official title: Pembrolizumab in Combination With Standard 1st Line Therapy (Lenvatinib / Chemotherapy) for Locally Advanced or Metastatic Poorly Differentiated or Anaplastic Thyroid Cancer
Sponsor: Saint Petersburg State University, Russia (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Lack of funding
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-12-28
Primary completion date: 2023-12-28
Completion date: 2023-12-28
Plan to share individual participant data: NO
Clinical trial NCT03872388: Atorvastatin in Treating Patients With Stage IIb-III Triple Negative Breast Cancer Who Did Not Achieve a Pathologic Complete Response After Receiving Neoadjuvant Chemotherapy
Official title: Atorvastatin in Triple-Negative Breast Cancer (TNBC) Patients Who Did Not Achieve a Pathologic Complete Response (pCR) After Receiving Neoadjuvant Chemotherapy, a Multicenter Pilot Study
Sponsor: M.D. Anderson Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Due to slow accrual
Enrollment: 6.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-09-23
Primary completion date: 2023-10-19
Completion date: 2023-10-19
Baseline population: 6 participants were accrued and assessed for eligibility and 4 patients were assigned to the cohort.
Clinical trial NCT04822701: A Study to Test BI 767551 in People With Mild to Moderate Symptoms of COVID-19
Official title: A Phase II/III Seamless, Randomized, Double-blind, Placebo-controlled, Parallel-group, Group-sequential Study to Evaluate Efficacy, Safety and Tolerability of BI 767551 for the Treatment of Symptomatic, Non-hospitalized Adults With Mild to Moderate COVID-19.
Sponsor: Boehringer Ingelheim (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: TERMINATED 
Why stopped: not due to safety reasons
Enrollment: 5.0 (ACTUAL)
Number of arms: 6.0
Start date: 2021-04-21
Primary completion date: 2021-07-02
Completion date: 2021-10-04
Baseline population: Treated set (TS): This subject set includes all subjects who received any amount of study drug.
Limitations and caveats: This trial was prematurely discontinued due to sponsor decision. 4 participants were enrolled in the Phase II Placebo intravenous (i.v.) + placebo inhaled group and 1 participant in the Placebo intravenous (i.v.) + BI 250 mg inhaled group. No patients were entered in the planned Phase II BI 10 milligrams (mg)/kilogram (kg) intravenous (i.v.) + placebo inhaled and BI 40 mg/kg i.v. + placebo inhaled groups. Phase III part was not conducted.
Plan to share individual participant data: YES
IPD sharing description: After the study is completed and the primary manuscript is accepted for publishing, researchers can use this following link https://www.mystudywindow.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed Document Sharing Agreement. Also, researchers can use the following link https://www.mystudywindow.com/msw/datasharing to find information in order to request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.~The data shared are the raw clinical study data sets.
IPD time frame: After all regulatory activities are completed in the United States (US) and European Union (EU) for the product and indication, and after the primary manuscript has been accepted for publication.
IPD access criteria: For study documents - upon signing of a 'Document Sharing Agreement'. For study data - 1. after the submission and approval of the research proposal (checks will be performed by both the independent review panel and the sponsor, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a 'Data Sharing Agreement'.
Clinical trial NCT02144142: Evaluation of the Kinetic Properties of an Autologous Microbiome Transplant in Adult Atopic Dermatitis Patients
Official title: Phase 2 Study Evaluating the Kinetic Properties of an Autologous Microbiome Transplant in Adult Atopic Dermatitis Patients
Sponsor: University of California, San Diego (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: This sub-study was not done because main study results reached significance.
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2015-07-31
Primary completion date: 2022-07-31
Completion date: 2022-07-31
Clinical trial NCT04618263: Safety and Tolerability of Single and Multiple Ascending Doses of GATE-101 in Normal Human Volunteers
Official title: A Randomized Double-blind, Placebo-controlled Single and Multiple Intravenous Ascending Dose Study of the Safety, Tolerability and Pharmacokinetics of GATE-101 in Normal Healthy Volunteers
Sponsor: Gate Neurosciences, Inc (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Reached biomarker endpoint
Enrollment: 18.0 (ACTUAL)
Number of arms: 12.0
Start date: 2020-10-26
Primary completion date: 2021-08-13
Completion date: 2021-08-13
Clinical trial NCT04524663: Oral Camostat Compared With Standard Supportive Care in Mild-Moderate COVID-19 Patients
Official title: A Phase 2 Randomized, Double Blinded, Placebo Controlled Study of Oral Camostat Mesilate Compared to Standard of Care in Subjects With Mild-Moderate COVID-19
Acronym: COPS-2003
Sponsor: Stanford University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 49.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-12-19
Primary completion date: 2021-05-15
Completion date: 2021-05-15
Plan to share individual participant data: NO
Clinical trial NCT04235959: A Study of Tirzepatide in Chinese Participants With Type 2 Diabetes Mellitus
Official title: A Multiple Dose Titration Study in Chinese Patients With Type 2 Diabetes Mellitus to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Tirzepatide
Sponsor: Eli Lilly and Company (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 24.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-10-21
Primary completion date: 2021-08-17
Completion date: 2021-08-17
Baseline population: All participants who received at least one dose of study drug.
Plan to share individual participant data: NO
Clinical trial NCT04640168: Adaptive COVID-19 Treatment Trial 4 (ACTT-4)
Official title: A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults (ACTT-4)
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) (NIH)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 1010.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-12-02
Primary completion date: 2021-05-18
Completion date: 2021-06-18
Baseline population: The population includes all participants enrolled.
Clinical trial NCT04416906: A Test and Treat Strategy in New HIV Diagnosis.
Official title: A Test and Treat Strategy in Barcelona: A Prospective Study in New HIV Diagnosis.
Acronym: Test&Treat
Sponsor: Fundacion Clinic per a la Recerca Biomédica (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 100.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-10-05
Primary completion date: 2023-05-11
Completion date: 2023-05-11
Plan to share individual participant data: UNDECIDED
IPD sharing description: A plan description will be provided once it is decided
Clinical trial NCT03514407: A Study of INCB059872 in Relapsed or Refractory Ewing Sarcoma
Official title: An Open-Label Phase 1b Study of the Safety, Tolerability, and Preliminary Antitumor Activity of INCB059872 in Participants With Relapsed or Refractory Ewing Sarcoma
Sponsor: Incyte Corporation (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Strategic Business Decision
Enrollment: 25.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-06-27
Primary completion date: 2020-06-25
Completion date: 2020-06-25
Plan to share individual participant data: NO
Clinical trial NCT02369874: Study of MEDI4736 Monotherapy and in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Head and Neck Cancer
Official title: A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 Monotherapy and MEDI4736 in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Acronym: EAGLE
Sponsor: AstraZeneca (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 736.0 (ACTUAL)
Number of arms: 3.0
Start date: 2015-09-09
Primary completion date: 2018-09-10
Completion date: 2020-11-13
Limitations and caveats: Multiple testing was performed for OS analysis in the intent-to-treat (ITT) population and OS analysis in the PD-L1 negative population for durvalumab + tremelimumab versus SoC only.
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Clinical trial NCT04290871: Nitric Oxide Gas Inhalation for Severe Acute Respiratory Syndrome in COVID-19.
Official title: Nitric Oxide Gas Inhalation Therapy for Severe Acute Respiratory Syndrome Due to COVID-19.
Acronym: NOSARSCOVID
Sponsor: Xijing Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: The study will start to enroll patients soon
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2023-01-16
Primary completion date: 2023-12-31
Completion date: 2024-04-01
Clinical trial NCT03841331: Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Chronic Pruritus of Unknown Origin
Official title: A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Chronic Pruritus of Unknown Origin
Sponsor: Vyne Therapeutics Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 233.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-01-22
Primary completion date: 2019-12-10
Completion date: 2020-01-21
Clinical trial NCT03703908: A Study of CCX140-B in Subjects With Primary FSGS and Nephrotic Syndrome
Official title: An Open Label, Intra-Subject Dose Escalation Study of CCX140-B in Subjects With Primary Focal Segmental Glomerulosclerosis (FSGS) and Nephrotic Syndrome
Sponsor: ChemoCentryx (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Program not advancing
Enrollment: 5.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-10-01
Primary completion date: 2020-06-24
Completion date: 2020-06-24
Limitations and caveats: The CL012_140 study was terminated early due to lack of efficacy in another study, CL011_140, investigating the use of CCX140-B.
Clinical trial NCT04973527: LCAR-T2C CAR-T Cells in Relapsed or Refractory CD4+ T Lymphocyte Tumor
Official title: A Phase I, Multicenter Study to Evaluate the Safety, Tolerability, and Efficacy of LCAR-T2C CAR-T Cells in Relapsed or Refractory CD4+ T Lymphocyte Tumor Patients
Sponsor: Beijing Boren Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Both the sponsors and collaborator are considering terminating the study
Enrollment: 9.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-07-02
Primary completion date: 2022-07-11
Completion date: 2022-07-20
Clinical trial NCT03938857: DOSE Trial of Opioid Sparing Effect
Official title: DEXMEDETOMIDINE OPIOID SPARING EFFECT IN MECHANICALLY VENTILATED CHILDREN: Phase 1b, Multicenter, Double Blind Randomized Controlled Dose Escalating Trial of Fentanyl vs. Fentanyl + Dexmedetomidine as the Initial Regimen for Maintenance of Sedation in Mechanically-ventilated, Critically Ill Children
Acronym: DOSE
Sponsor: Duke University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Enrollment challenging during the pandemic COVID 19
Enrollment: 30.0 (ACTUAL)
Number of arms: 4.0
Start date: 2019-07-18
Primary completion date: 2020-10-21
Completion date: 2020-11-06
Baseline population: Study was prematurely terminated and no participants were enrolled in the Fen. SOC+Dex.(.5mcg/kg + .75mcg/kg/hr) group.
Plan to share individual participant data: NO
Clinical trial NCT03427320: Imaging of Advanced Tumours Using [131]I-IAZA
Official title: A Radiopharmacokinetic and Radiodosimetric Phase I/II Imaging Study of 1-alpha-D-(5-[131I]Iodo-5-deoxyarabinofuranosyl)-2-Nitroimidazole (131I-IAZA) in Patients With Locally Advanced or Metastatic Solid Tumors
Sponsor: University of Alberta (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: WITHDRAWN 
Why stopped: Abandoned.
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-12-31
Primary completion date: 2021-04-30
Completion date: 2021-04-30
Plan to share individual participant data: NO
Clinical trial NCT03445663: Study Evaluating AMG 424 in Subjects With Multiple Myeloma
Official title: A Phase 1, First-in-Human, Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 424 in Subjects With Multiple Myeloma
Sponsor: Xencor, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Previous sponsor business decision not to proceed with the AMG 424 asset.
Enrollment: 27.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-07-31
Primary completion date: 2020-06-19
Completion date: 2020-06-19
Plan to share individual participant data: YES
IPD sharing description: De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request
IPD time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication (or other new use) have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.
IPD access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the link below.
Clinical trial NCT03907033: Liposomal Bupivacaine in Vaginal Hysterectomy
Official title: Preemptive Local Analgesia With Liposomal Bupivacaine in Vaginal Hysterectomy: A Randomized Controlled Study
Sponsor: Mayo Clinic (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Insufficient funding to continue with study activities
Enrollment: 28.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-09-03
Primary completion date: 2021-07-23
Completion date: 2021-07-23
Plan to share individual participant data: NO
Clinical trial NCT04842981: Interleukin-6 Inhibitors and Drug-drug Interactions in Patients With Rheumatoid Arthritis
Official title: Interleukin-6 Inhibitors and Drug-drug Interactions in Patients With Rheumatoid Arthritis
Sponsor: University of Southern Denmark (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Slow recruitment due to COVID19.
Enrollment: 3.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-05-25
Primary completion date: 2022-09-30
Completion date: 2022-09-30
Plan to share individual participant data: NO
Clinical trial NCT03488225: Combination Chemotherapy and Inotuzumab Ozogamicin in Treating Patients With B Acute Lymphoblastic Leukemia
Official title: Phase II Study of the Hyper-CVAD Regimen in Sequential Combination With Inotuzumab Ozogamicin as Frontline Therapy for Adults With B-Cell Lineage Acute Lymphocytic Leukemia
Sponsor: M.D. Anderson Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: the study was closed early due to competing trials
Enrollment: 4.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-03-28
Primary completion date: 2020-04-02
Completion date: 2020-04-02
Clinical trial NCT03620890: Detemir Versus NPH for Type 2 Diabetes Mellitus in Pregnancy
Official title: Detemir Versus NPH for Type 2 Diabetes Mellitus in Pregnancy: a Comparative-effectiveness, Open Label, Randomized Controlled Trial
Acronym: Determin
Sponsor: The University of Texas Health Science Center, Houston (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 108.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-09-04
Primary completion date: 2020-07-29
Completion date: 2020-07-29
Plan to share individual participant data: NO
Clinical trial NCT04256603: Evaluation of Initiation Time on the Efficacy of Gabapentin in Treating Neuropathic Pain in SCI
Official title: Evaluation of Initiation Time on the Efficacy of Gabapentin in Treating Neuropathic Pain in Spinal Cord Injury (SCI)
Sponsor: MetroHealth Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 27.0 (ACTUAL)
Number of arms: 3.0
Start date: 2019-08-01
Primary completion date: 2020-03-30
Completion date: 2020-04-01
Plan to share individual participant data: NO
Clinical trial NCT01524783: Everolimus Plus Best Supportive Care vs Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced Neuroendocrine Tumors (GI or Lung Origin)
Official title: A Randomized, Double-blind, Multicenter, Phase III Study of Everolimus (RAD001) Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced NET of GI or Lung Origin
Acronym: RADIANT-4
Sponsor: Novartis (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 302.0 (ACTUAL)
Number of arms: 2.0
Start date: 2012-03-30
Primary completion date: 2014-11-28
Completion date: 2020-08-07
Plan to share individual participant data: YES
IPD sharing description: Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Clinical trial NCT04988035: ACTIV-5 / Big Effect Trial (BET-C) for the Treatment of COVID-19
Official title: A Multicenter Platform Trial of Putative Therapeutics for the Treatment of COVID-19 in Hospitalized Adults
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) (NIH)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 201.0 (ACTUAL)
Number of arms: 4.0
Start date: 2021-08-03
Primary completion date: 2022-04-23
Completion date: 2022-04-23
Baseline population: The intention-to-treat (ITT) population includes all participants who were enrolled and randomized.
Clinical trial NCT02117466: Image Guided Treatment Optimization With Cetuximab for Patients With Metastatic Colorectal Cancer
Official title: Image Guided Treatment Optimization With Cetuximab for Patients With Metastatic Colorectal Cancer
Acronym: IMPACT-CRC
Sponsor: Amsterdam UMC, location VUmc (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Primary endpoint could no longer be reached.
Enrollment: 85.0 (ACTUAL)
Number of arms: 2.0
Start date: 2014-04-30
Primary completion date: 2021-01-31
Completion date: 2021-01-31
Clinical trial NCT04291456: Minocycline in MS: Confirmation of Benefit
Official title: Open-Label Trial of Minocycline in Early Multiple Sclerosis: Confirmation of Treatment Benefit
Acronym: MS
Sponsor: University of Calgary (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Completion is not possible due to recruitment concerns
Enrollment: 9.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-01-31
Primary completion date: 2022-12-16
Completion date: 2022-12-31
Plan to share individual participant data: NO
Clinical trial NCT05351047: A Study to Assess Safety, Tolerability, PK and PD of AZD2373 in Healthy Male Participants of Sub-Saharan West African Ancestry
Official title: A Phase I, Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD2373 Following Multiple Ascending Dose Administration to Healthy Male Participants of Sub-Saharan West African Ancestry
Sponsor: AstraZeneca (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 24.0 (ACTUAL)
Number of arms: 5.0
Start date: 2022-04-04
Primary completion date: 2023-07-06
Completion date: 2023-07-06
Clinical trial NCT01462890: Evaluation of Optimal Treatment Duration of Bevacizumab Combination With Standard Chemotherapy in Patients With Ovarian Cancer
Official title: A Prospective Randomised Phase III Trial to Evaluate Optimal Treatment Duration of First-line Bevacizumab in Combination With Carboplatin and Paclitaxel in Patients With Primary Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer
Acronym: BOOST
Sponsor: AGO Study Group (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 927.0 (ACTUAL)
Number of arms: 2.0
Start date: 2011-11-30
Primary completion date: 2020-12-31
Completion date: 2021-12-31
Plan to share individual participant data: NO
Clinical trial NCT03912818: Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder Cancer
Official title: Phase 2 Open Label Study of Durvalumab With Neoadjuvant Chemotherapy in Variant Histology Bladder Cancer
Sponsor: Stanford University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Difficulty with enrollment
Enrollment: 7.0 (ACTUAL)
Number of arms: 3.0
Start date: 2019-04-10
Primary completion date: 2022-08-11
Completion date: 2022-08-11
Limitations and caveats: The study did not achieve its planned enrollment size and did not achieve statistical power.
Plan to share individual participant data: NO